Molecular screening of familial hypercholesterolemia in Icelanders. (1st October 2020)

• Record Type: Journal Article
• Authors: Kellogg, Greg; Thorsson, Bolli; Cai, Ying; Wisotzkey, Robert; Pollock, Andrew; Akana, Matthew; Fox, Rebecca; Jansen, Michael; Gudmundsson, Elias F.; Patel, Bonny; Chang, Chihyu; Jaremko, Malgorzata; Puig, Oscar; Gudnason, Vilmundur; Emilsson, Valur
• Is Part Of: Scandinavian journal of clinical & laboratory investigation. Volume 80:Number 6(2020)
• Page Start: 508
• Page End: 514
• Publication Date: 2020-10-01
• Subjects: Cholesterol -- dyslipidemias -- high-throughput nucleotide sequencing -- genetic testing -- LDLR mutations; Clinical biochemistry -- Periodicals; Physiology, Pathological -- Periodicals; Physiology, Experimental -- Periodicals; Medicine -- Research -- Periodicals; Clinical medicine -- Periodicals; 616.0072
• DOI: 10.1080/00365513.2020.1795919
• Languages: English
• ISSNs: 0036-5513

Abstract

Abstract: Familial hypercholesterolemia (FH) is a monogenic disease characterized by a lifelong exposure to high LDL-C levels that can lead to early onset coronary heart disease (CHD). The main causes of FH identified to date include loss-of-function mutations in LDLR or APOB, or gain-of-function mutations in PCSK9 . Early diagnosis and genetic testing of FH suspects is critical for improved prognosis of affected individuals as lipid lowering treatments are effective in preventing CHD related morbidity and mortality. In the present study, we carried out a comprehensive screening, using a next-generation sequencing (NGS) panel, for FH culprit mutations in two Icelandic studies representative of either FH families or the general population. We confirmed all previously known mutations in the FH families, and identified two subjects that had been misdiagnosed clinically at young age. We identified six new mutations in the Icelandic FH families and detected three pathogenic mutations in the general population-based study. The application of the NGS panel revealed substantial diagnostic yields in identifying pathogenic mutations, or 68.2% of those with definite clinical diagnosis of FH in the family material and 5.6-fold enrichment in the population-based genetic testing.